- Home
- AVTX vs INZY Comparison
AVTX vs INZY Comparison
Compare AVTX & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- INZY
- Stock Information
- Founded
- AVTX 2011
- INZY 2015
- Country
- AVTX United States
- INZY United States
- Employees
- AVTX N/A
- INZY N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- INZY Health Care
- Exchange
- AVTX Nasdaq
- INZY Nasdaq
- Market Cap
- AVTX 57.4M
- INZY 64.9M
- IPO Year
- AVTX 2015
- INZY 2020
- Fundamental
- Price
- AVTX $4.25
- INZY $1.15
- Analyst Decision
- AVTX Strong Buy
- INZY Strong Buy
- Analyst Count
- AVTX 6
- INZY 9
- Target Price
- AVTX $34.20
- INZY $17.22
- AVG Volume (30 Days)
- AVTX 66.4K
- INZY 1.1M
- Earning Date
- AVTX 05-20-2025
- INZY 05-20-2025
- Dividend Yield
- AVTX N/A
- INZY N/A
- EPS Growth
- AVTX N/A
- INZY N/A
- EPS
- AVTX N/A
- INZY N/A
- Revenue
- AVTX $441,000.00
- INZY N/A
- Revenue This Year
- AVTX N/A
- INZY N/A
- Revenue Next Year
- AVTX N/A
- INZY N/A
- P/E Ratio
- AVTX N/A
- INZY N/A
- Revenue Growth
- AVTX N/A
- INZY N/A
- 52 Week Low
- AVTX $4.15
- INZY $0.72
- 52 Week High
- AVTX $16.00
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- AVTX 31.02
- INZY 50.96
- Support Level
- AVTX $4.80
- INZY $1.18
- Resistance Level
- AVTX $5.26
- INZY $1.63
- Average True Range (ATR)
- AVTX 0.45
- INZY 0.20
- MACD
- AVTX 0.03
- INZY 0.02
- Stochastic Oscillator
- AVTX 11.96
- INZY 23.66
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.